Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab ...

Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

Adocia has announced the filing of a patent for its new long-acting peptide platform, AdoXLong, aimed at improving treatment options for diabetes and obesity. The French biopharmaceutical company said ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of nephropathic cystinosis – a rare, progressive and life-limiting condition ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

MND isn’t incurable, it’s underfunded ...

Women’s health issues have historically been under-researched, marginalised and underserved. This systemic neglect has led to ...

Rebuilding the clinical trials landscape in the UK ...

What is, exactly, going on with the NHS at the moment? You could be forgiven for thinking the fireworks of this summer’s ...